A Phase 2 interventional study of AG-348 in Thalassemia, sponsored by Agios Pharmaceuticals, Inc.. Active, not recruiting at 4 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-30.
Sponsored by Agios Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies in Thalassemia with a site in United States — 9 open to participants now, 20 under way, 8 of them phase 3. Thalassemia · United States.
Among the 104 studies in Thalassemia with a site in United States, this one is the 48th largest by enrollment of the 81 interventional ones that give a count, is one of 6 that started in 2019, is one of 32 in phase 2, reaches primary completion later than 1 of the 19 other live ones, and was the 81st registered.
250 studies on the registry are indexed under Thalassemia; 43 are open to participants now.
Browse Thalassemia studies →9 of the 104 studies in Thalassemia with a site in United States are open now. Recruiting first, the newest first:
Agios Pharmaceuticals, Inc. · Sites in United States
Ages 1–17
Agios Pharmaceuticals, Inc. · Sites in United States
Ages 1–17
Novo Nordisk A/S · Sites in United States, Canada, Egypt and 14 more countries
Ages 2+
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 18–100
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 2–50
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 28 Thalassemia studies recruiting now, 7 (25%) set no upper age limit and 18 (64%) stop at 75 or younger; 22 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 44 · Phase 3 13 · Phase 4 2
First in 1985; this study’s year is marked. 6 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 33 across 170 interventional studies indexed under Thalassemia.
Median enrollment 24 across the 81 interventional studies, 125 across the 20 observational. Of the 78 that completed or were terminated, 33 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 104 have an industry lead sponsor. The 10 most frequent:
Agios Pharmaceuticals, Inc. is the lead sponsor of 52 studies on the registry; 6 are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 4 (17%) have results posted.
Agios Pharmaceuticals, Inc. has 6 studies filed under Thalassemia — fewer than ten, so there is no comparison to draw.
7 of the studies in Thalassemia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05477563Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease | 2027-06-09 |
| NCT05356195Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) | 2027-11-14 |
| NCT07064941University of California, San FranciscoEffect of Exercise on Body Composition and Bone Health in Patients With Thalassemia | 2026-12-30 |
| NCT03249831City of Hope Medical CenterA Blood Stem Cell Transplant for Sickle Cell Disease | 2027-01-25 |
| NCT05736419Memorial Sloan Kettering Cancer CenterA Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) | 2027-02-09 |
Add all 7 to your calendar (.ics) → With an account.
Among the 104 studies in Thalassemia with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study AG348-C-010 is a multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of treatment with AG-348 in adult participants with non-transfusion-dependent thalassemia (NTDT). This study includes a core period (up to 24 weeks) followed by an extension period (up to 10 years) for eligible participants. 20 participants with NTDT were enrolled. The initial dose of AG-348 was 50 milligrams (mg) twice daily (BID) with one potential dose-level increase to 100 mg BID at the Week 6 visit based on the participant's safety and hemoglobin (Hb) concentrations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with alpha or beta thalassemia received AG-348 50 mg twice daily (BID), orally up to Week 6. Following Week 6, depending on the participants' safety and hemoglobin (Hb) concentrations, they could undergo one potential dose-level increase from 50 to 100 mg BID. After completion of the Core Period of 24 weeks, participants were eligible to continue to receive AG-348 in the Extension Period which is up to 10 years.
Drug: AG-348
AG-348 tablet orally BID
Also known as: Mitapivat
Percentage of Participants Achieving a Hemoglobin Response (HR)
HR was defined as a ≥1.0 gram per deciliter (g/dL) increase in Hb concentration from Baseline at 1 or more assessments between Week 4 and Week 12 (inclusive). A participant's Baseline Hb concentration was defined as the average of all the participant's available Hb concentrations during the screening period up to the first dose of study drug.
Time frame: Up to 12 weeks
Average Change From Baseline in Hb Concentrations From Week 12 to Week 24
A participant's Baseline Hb concentration was defined as the average of all the participant's available Hb concentrations during the screening period up to the first dose of study drug.
Time frame: Baseline, Week 12 to Week 24
Percentage of Participants Achieving a Sustained Hb Response (sHR)
sHR was defined as achieving HR and achieving a ≥1.0 g/deciliter (dL) increase in Hb concentration at 2 or more evaluable Hb assessments out of the 4 scheduled assessments between the Week 12 visit and Week 24 visit.
Time frame: Week 12 to Week 24
Percentage of Participants Achieving a Delayed Hb Response
Delayed Hb response was defined as not achieving HR and achieving a ≥1.0 g/dL increase in Hb concentration at 1 or more Hb assessments after Week 12.
Time frame: Week 12 to Week 24
Change From Baseline in Hb Concentration Over the Duration of the Extension Period
Time frame: Baseline up to approximately 10.5 years
Time to First ≥1.0 g/dL Increase in Hb Concentration
Time frame: Up to Week 24
Change From Baseline in Reticulocyte Count
Time frame: Up to approximately 10.5 years
Change From Baseline in Bilirubin
Time frame: Up to approximately 10.5 years
Change From Baseline in Lactate Dehydrogenase (LDH)
Time frame: Up to approximately 10.5 years
Change From Baseline in Haptoglobin
Time frame: Up to approximately 10.5 years
Change From Baseline in Nucleated Red Blood Cells (NRBCs)
Time frame: Up to approximately 10.5 years
Change From Baseline in Erythropoietin (EPO)
Time frame: Up to approximately 10.5 years
Change From Baseline in Soluble Transferrin Receptor
Time frame: Up to approximately 10.5 years
Drug Concentrations Over Time for AG-348
Time frame: Predose (60 minutes) and 0.00 hour, 0.50 hour, 1 hour, 2 hours, 4 hours, and 8 hours postdose on Day 1 and Week 12
AUC0-8h: Area Under the Plasma Concentration-time Curve From Time 0 to 8 Hours of AG-348
Time frame: Predose (60 minutes) and 30 minutes, 1 hour, 2 hours, 4 hours, and 8 hours postdose on Day 1 and Week 12
AUC0-t: Area Under the Plasma Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration of AG-348
Time frame: Predose (60 minutes) and 30 minutes, 1 hour, 2 hours, 4 hours, and 8 hours postdose on Day 1 and Week 12
Cmax: Maximum Observed Plasma Concentration of AG-348
Time frame: Predose (60 minutes) and 30 minutes, 1 hour, 2 hours, 4 hours, and 8 hours postdose on Day 1 and Week 12
Tmax: Time to Reach the Maximum Plasma Radioactivity Concentration (Cmax)
Time frame: Predose (60 minutes) and 30 minutes, 1 hour, 2 hours, 4 hours, and 8 hours postdose on Day 1 and Week 12
Tlast: Time of the Last Quantifiable Concentration of AG-348
Time frame: Predose (60 minutes) and 30 minutes, 1 hour, 2 hours, 4 hours, and 8 hours postdose on Day 1 and Week 12
Ctrough: Observed Plasma Concentration at the End of a Dosing Interval of AG-348
Time frame: Predose (60 minutes) and 30 minutes, 1 hour, 2 hours, 4 hours, and 8 hours postdose on Day 1 and Week 12
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), AEs of Special Interest (AESIs), and TEAEs Leading to Study Drug Dose Reduction, Study Drug Interruption, and Study Drug Discontinuation
An AE is any unfavorable and unintended sign, symptom, or disease, whether or not related to the investigational product. A TEAE was defined as any AE with onset post study drug treatment. An SAE was defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is medically important. AESIs are predefined AEs that required close monitoring and prompt reporting to the sponsor. AESIs included protocol-specified transaminase increase.
Time frame: From signing the inform consent form up to data cut-off date: 20 August 2020 (Up to approximately 19 months)
Participants took part in the study at 4 investigative sites in the United States, Canada, and United Kingdom from 28 December 2018 to 30 September 2030. Results are reported for the primary and secondary outcome measures for the 24-week Core Period (data cut-off date: 20 August 2020). The Extension Period of this study is ongoing.
| Milestone | AG-348 |
|---|---|
| Started | 20 |
| Completed | 19 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
| Milestone | AG-348 |
|---|---|
| Started | 19 |
| Completed | 0 |
| Not completed | 19 |
| Withdrew: Withdrawal of consent | 1 |
| Withdrew: Physician decision | 1 |
| Withdrew: Ongoing | 17 |
HR was defined as a ≥1.0 gram per deciliter (g/dL) increase in Hb concentration from Baseline at 1 or more assessments between Week 4 and Week 12 (inclusive). A participant's Baseline Hb concentration was defined as the average of all the participant's available Hb concentrations during the screening period up to the first dose of study drug.
| percentage of participants | AG-348 |
|---|---|
| Percentage of Participants Achieving a Hemoglobin Response (HR) | 80.0 (59.90 to 92.86) |
A participant's Baseline Hb concentration was defined as the average of all the participant's available Hb concentrations during the screening period up to the first dose of study drug.
| grams per liter (g/L) | AG-348 |
|---|---|
| Baseline | 79.44 ± 13.690 |
| Average Change from Baseline: Week 12 to 24 | 13.01 ± 6.283 |
sHR was defined as achieving HR and achieving a ≥1.0 g/deciliter (dL) increase in Hb concentration at 2 or more evaluable Hb assessments out of the 4 scheduled assessments between the Week 12 visit and Week 24 visit.
| percentage of participants | AG-348 |
|---|---|
| Percentage of Participants Achieving a Sustained Hb Response (sHR) | 65.0 (44.20 to 82.27) |
Delayed Hb response was defined as not achieving HR and achieving a ≥1.0 g/dL increase in Hb concentration at 1 or more Hb assessments after Week 12.
| percentage of participants | AG-348 |
|---|---|
| Percentage of Participants Achieving a Delayed Hb Response | 10.0 (1.81 to 28.26) |
Results for this outcome have not been posted.
| weeks | AG-348 |
|---|---|
| Time to First ≥1.0 g/dL Increase in Hb Concentration | 4.54 ± 3.204 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
| nanograms per milliliter (ng/mL) | AG-348 |
|---|---|
| AG-348 50 mg: 0.00 Hour, Day 1 | NA ± NA |
| AG-348 50 mg: 0.50 Hour, Day 1 | NA ± NA |
| AG-348 50 mg: 1 Hour, Day 1 | 785.2 ± 64.6 |
| AG-348 50 mg: 2 Hour, Day 1 | 694.5 ± 26.6 |
| AG-348 50 mg: 4 Hour, Day 1 | 369.2 ± 29.4 |
| AG-348 50 mg: 8 Hour, Day 1 | 128.9 ± 55.1 |
| AG-348 100 mg: 0.00 Hour, Week 12 | 39.39 ± 117.1 |
| AG-348 100 mg: 0.50 Hour, Week 12 | 1030 ± 137.7 |
| AG-348 100 mg: 1 Hour, Week 12 | 1442 ± 30.6 |
| AG-348 100 mg: 2 Hour, Week 12 | 740.1 ± 76.3 |
| AG-348 100 mg: 4 Hour, Week 12 | 302.8 ± 75.2 |
| AG-348 100 mg: 8 Hour, Week 12 | 77.35 ± 48.2 |
| nanograms*hour per milliliter (ng*h/mL) | AG-348 |
|---|---|
| AG-348 50 mg: Day 1 | 3083.3 ± 25.6 |
| AG-348 100 mg: Week 12 | 3384.4 ± 65.7 |
| ng*h/mL | AG-348 |
|---|---|
| AG-348 50 mg: Day 1 | 3083.5 ± 25.6 |
| AG-348 100 mg: Week 12 | 3384.4 ± 65.7 |
| ng/mL | AG-348 |
|---|---|
| AG-348 50 mg: Day 1 | 968.9 ± 38.1 |
| AG-348 100 mg: Week 12 | 1476 ± 93.5 |
| hours | AG-348 |
|---|---|
| AG-348 50 mg: Day 1 | 1.07 (0.48 to 4.07) |
| AG-348 100 mg: Week 12 | 0.53 (0.43 to 2.03) |
| hours | AG-348 |
|---|---|
| AG-348 50 mg: Day 1 | 7.60 (7.50 to 8.02) |
| AG-348 100 mg: Week 12 | 7.55 (7.50 to 7.95) |
| ng/mL | AG-348 |
|---|---|
| AG-348 100 mg: Week 12 | 37.34 ± 117.7 |
An AE is any unfavorable and unintended sign, symptom, or disease, whether or not related to the investigational product. A TEAE was defined as any AE with onset post study drug treatment. An SAE was defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is medically important. AESIs are predefined AEs that required close monitoring and prompt reporting to the sponsor. AESIs included protocol-specified transaminase increase.
| percentage of participants | AG-348 |
|---|---|
| TEAEs | 85.0 |
| SAEs | 5.0 |
| AESIs | 5.0 |
| TEAEs Leading to Study Drug Dose Reduction | 15.0 |
| TEAEs Leading to Study Drug Interruption | 5.0 |
| TEAEs Leading to Study Drug Discontinuation | 5.0 |
Collected over Up to completion of the Core Period data cut-off date: 20 August 2020 (Up to approximately 19 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AG-348 | 0/20 (0%) | 1/20 (5%) | 17/20 (85%) |
| Event | AG-348 |
|---|---|
| Renal impairmentRenal and urinary disorders | 1/20 |
| Event | AG-348 |
|---|---|
| Initial insomniaPsychiatric disorders | 10/20 |
| DizzinessNervous system disorders | 6/20 |
| HeadacheNervous system disorders | 5/20 |
| DyspepsiaGastrointestinal disorders | 4/20 |
| FatigueGeneral disorders | 4/20 |
| Upper respiratory tract infectionInfections and infestations | 4/20 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/20 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 4/20 |
| Abdominal painGastrointestinal disorders | 3/20 |
| DiarrhoeaGastrointestinal disorders | 3/20 |
Full Analysis Set (FAS) included all participants who received at least 1 dose of study treatment.
| Age, Continuous(years) | AG-348 |
|---|---|
| Mean | 45.3 ± 11.81 |
| Sex: Female, Male(Participants) | AG-348 |
|---|---|
| Female | 15 |
| Male | 5 |
| Ethnicity (NIH/OMB)(Participants) | AG-348 |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 19 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | AG-348 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 10 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 1 |
| White | 4 |
| More than one race | 0 |
| Unknown or Not Reported | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2019 to primary completion in Aug 2020, 17 months.
Results were first posted in Nov 2021, 1 year 2 months after primary completion.
Of 25 phase 2 interventional studies under Thalassemia, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 67. This study's 17 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mitapivat